Tags : HER2-Negative

Regulatory

AstraZeneca and Merck’s Lynparza (olaparib) Receive EU’s Approval as a

Shots: The approval is based on P-III OlympiAD trial assessing Lynparza (300mg, bid) vs CT (capecitabine, eribulin or vinorelbine) in 302 patients with germline BRCA1- and/or BRCA2-mutated, HER2-negative (HR-positive or triple negative) breast cancer  The P-III study results: 42% reduction in the risk of disease progression or death; PFS (7.0mos. vs 4.2mos.); ORR (52% vs […]Read More